ConductScience.org, home

Paper42036664

Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.

Lu N and 3 others. J Hematol Oncol, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming. Papers, record 42036664. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42036664

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.
PubMed
Journal
J Hematol Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-11-04
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lu NNa
2Yan BBin
3Li YQYu-Qiang
4Wan JLJing-Lei

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Tumor MicroenvironmentMajor topic
ImmunoconjugatesMajor topic
Breast NeoplasmsMajor topic
Antineoplastic Agents, ImmunologicalMajor topic
Humans
Female
Drug Delivery Systems
Animals

Source PubMed

Download CSV of topics

References106

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139575243Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies.Front Immunol2024https://conductscience.org/library/papers/39575243PubMed
238153656Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.Arch Pharm Res2024https://conductscience.org/library/papers/38153656PubMed
333408395Method of the Year: spatially resolved transcriptomics.Nat Methods2021https://conductscience.org/library/papers/33408395PubMed
431825192Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.N Engl J Med2020https://conductscience.org/library/papers/31825192PubMed
531548545Breast cancer.Nat Rev Dis Primers2019https://conductscience.org/library/papers/31548545PubMed
640175391Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd).Nat Commun2025https://conductscience.org/library/papers/40175391PubMed
738614094A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response.Cell Rep Med2024https://conductscience.org/library/papers/38614094PubMed
830664738Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal.Nat Immunol2019https://conductscience.org/library/papers/30664738PubMed
939376738Next-generation spatial transcriptomics: unleashing the power to gear up translational oncology.MedComm (2020)2024https://conductscience.org/library/papers/39376738PubMed
1036495879Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.Lancet2023https://conductscience.org/library/papers/36495879PubMed
1124667376Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.Sci Signal2014https://conductscience.org/library/papers/24667376PubMed
1239786401OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.Mol Cancer Ther2025https://conductscience.org/library/papers/39786401PubMed
1338951909A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance.Breast Cancer Res2024https://conductscience.org/library/papers/38951909PubMed
1428480899Immunosuppressive cell death in cancer.Nat Rev Immunol2017https://conductscience.org/library/papers/28480899PubMed
1538572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
1615864276ERBB receptors and cancer: the complexity of targeted inhibitors.Nat Rev Cancer2005https://conductscience.org/library/papers/15864276PubMed
1740460679The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.ESMO Open2025https://conductscience.org/library/papers/40460679PubMed
1834782633A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.Sci Rep2021https://conductscience.org/library/papers/34782633PubMed
1941280925The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data.Front Immunol2025https://conductscience.org/library/papers/41280925PubMed
2040364727A pH-Sensitive Nanosized Covalent-Organic Polymer for Enhanced Tumor Photodynamic Immunotherapy by Hypoxia Relief and STAT3 Inhibition.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40364727PubMed

See all 106 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42711696Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.J Hematol Oncol2026https://conductscience.org/library/papers/42711696

Source PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AZIN2113451PubTator's text mininghttps://conductscience.org/library/genes/113451NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
TACSTD24070PubTator's text mininghttps://conductscience.org/library/genes/4070NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42036664

GET https://conductscience.org/api/papers/v1/42036664/references?page=2